Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 5

Augmentation treatment in major depressive disorder: focus on aripiprazole

Authors J Craig Nelson, Andrei Pikalov, Robert M Berman

Published 10 October 2008 Volume 2008:4(5) Pages 937—948

DOI http://dx.doi.org/10.2147/NDT.S3369

Review by Single-blind

Peer reviewer comments 3

J Craig Nelson1, Andrei Pikalov2, Robert M Berman3

1University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA

Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.

Keywords: major depression, antipsychotic, mood disorder, aripiprazole

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Neuropsychiatric Disease and Treatment 2011, 7:303-312

Published Date: 24 May 2011

Readers of this article also read:

Bladder cancer in the elderly patient: challenges and solutions

Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, Mohile SG, Fung C

Clinical Interventions in Aging 2015, 10:939-949

Published Date: 10 June 2015

Predictors of quality of life among individuals with schizophrenia

Suttajit S, Pilakanta S

Neuropsychiatric Disease and Treatment 2015, 11:1371-1379

Published Date: 28 May 2015

The association of post-stroke anhedonia with salivary cortisol levels and stroke lesion in hippocampal/parahippocampal region

Terroni L, Amaro Jr E, Iosifescu DV, Mattos P, Yamamoto FI, Tinone G, Conforto AB, Sobreiro MFM, Guajardo VD, De Lucia MC, Moreira AC, Scaff M, Leite CC, Fraguas R

Neuropsychiatric Disease and Treatment 2015, 11:233-242

Published Date: 3 February 2015

Posttraumatic stress symptoms, dissociation, and alexithymia in an Italian sample of flood victims

Craparo G, Gori A, Mazzola E, Petruccelli I, Pellerone M, Rotondo G

Neuropsychiatric Disease and Treatment 2014, 10:2281-2284

Published Date: 28 November 2014

Cyclophosphamide-induced symptomatic hyponatremia, a rare but severe side effect: a case report

Elazzazy S, Mohamed AE, Gulied A

OncoTargets and Therapy 2014, 7:1641-1645

Published Date: 30 September 2014

Perioperative and postoperative risk factors for corneal graft failure

Yu AL, Kaiser M, Schaumberger M, Messmer E, Kook D, Welge-Lussen U

Clinical Ophthalmology 2014, 8:1641-1647

Published Date: 28 August 2014

Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients

Zhao HY, Ma GW, Zou BY, Li M, Lin SX, Zhao LP, Guo Y, Huang Y, Tian Y, Xie D, Zhang L

OncoTargets and Therapy 2014, 7:1301-1310

Published Date: 16 July 2014

Seasonal changes in nasal cytology in mite-allergic patients

Gelardi M, Peroni DG, Incorvaia C, Quaranta N, De Luca C, Barberi S, Dell'Albani I, Landi M, Frati F, de Beaumont O

Journal of Inflammation Research 2014, 7:39-44

Published Date: 28 March 2014

Potential of antibody–drug conjugates and novel therapeutics in breast cancer management

Lianos GD, Vlachos K, Zoras O, Katsios C, Cho WC, Roukos DH

OncoTargets and Therapy 2014, 7:491-500

Published Date: 24 March 2014

Reproducibility of the heat/capsaicin skin sensitization model in healthy volunteers

Cavallone LF, Frey K, Montana MC, Joyal J, Regina KJ, Petersen KL, Gereau RW

Journal of Pain Research 2013, 6:771-784

Published Date: 7 November 2013